[Ip-health] CSO strategy meeting 5 September: How to achieve Open Access (OA) to published research results in Horizon 2020

Tessel Mellema tessel at haieurope.org
Fri Aug 24 02:42:39 PDT 2012


CSO strategy meeting:

How to achieve Open Access (OA)

to published research results in Horizon 2020

Date: Wednesday, 5th September

Time: 11h00 -13h00

Place: A3E-2, European Parliament, Brussels

For: civil society organizations & other stakeholders working to promote
OA

 

The Transatlantic Consumer Dialogue (TACD) and Health Action
International (HAI) Europe host a strategy meeting for civil society and
other interested stakeholders working to promote Open Access to
published research results under the EU multi-annual 2014-2020 framework
programme for research and development: Horizon2020. 

This informal strategy meeting will be used to discuss with all
participants the following issues:

*         Share information on the state of play: What is happening in
the European Council, European Commission and European Parliament.

*         Co-ordinate action in the European Parliament for September to
push back on proposed amendments that may jeopardize Open Access in
Horizon2020.

*         Establish a network to facilitate coordination to achieve a
clear mandate for OA in Horizon 2020.

 

Please register by sending an email before August the 31st to
laurarossy at hotmail.com

Note-to get access badge to the European Parliament, please, include the
following information:

full name, date of birth, nationality, type of ID (passport, ID, driving
license) and ID number.

 

 

 

 

Tessel Mellema

Project Officer - Trade, Innovation & Access to Medicines

 

Health Action International (HAI) Europe

Overtoom 60 II, 1054 HK Amsterdam 

t. +31 20 683 3684

f. +31 20 685 5002

e. Tessel at haieurope.org <mailto:Tessel at haieurope.org>  

w. www.haieurope.org <http://www.haieurope.org> 

 

Health Action International (HAI) is an independent, global network
working to increase access to essential medicines and improve their
rational use through research excellence and evidence-based advocacy.

 

Important Email Information:

The information contained in this email is confidential and may be
legally privileged.  It is intended solely for the addressee and is for
the exclusive use of the intended recipient(s). If you are not the
intended recipient(s), please note that any form of disclosure,
distribution, copying or use of this communication or the information in
it or in any attachments is strictly prohibited and may be unlawful. If
you are not the intended addressee, please contact the sender and
dispose of this e-mail immediately. Any opinions expressed are those of
the author, not of HAI.

 




More information about the Ip-health mailing list